Analyst Research

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cardiome Pharma Corp announces at-the-market offering


Tuesday, 18 Feb 2014 07:45am EST 

Cardiome Pharma Corp:Enters into an At Market Sales Issuance Agreement with MLV & Co. LLC (MLV).Says pursuant to which the company may from time to time sell, through at-the-market (ATM) offerings and MLV as agent, such common shares as would have an aggregate offer price of up to $30,000,000.Say it may sell up to$8,900,000 of its common shares in an ATM offering.Says intends to use the proceeds from sales related to the ATM offering, if any, primarily for working capital and general corporate purposes.Says including to fund expansion of sales and marketing efforts for BRINAVESS and AGGRASTAT in Europe and other parts of the world.Say for funding clinical development and regulatory costs of vernakalant (IV) and vernakalant (oral), and for advancement of Cardiome's other business objectives. 

Company Quote

9.07
0.06 +0.67%
31 Jul 2015